keyword
MENU ▼
Read by QxMD icon Read
search

Liver cancer immunotherapy

keyword
https://www.readbyqxmd.com/read/29785403/immunotherapy-for-hepatocellular-carcinoma-current-advances-and-future-expectations
#1
REVIEW
Yingjun Xie, Yien Xiang, Jiyao Sheng, Dan Zhang, Xiaoxiao Yao, Yongsheng Yang, Xuewen Zhang
Primary liver cancer is a common kind of digestive cancers with high malignancy, causing 745,500 deaths each year. Hepatocellular carcinoma is the major pathological type of primary liver cancer. Traditional treatment methods for patients with hepatocellular carcinoma have shown poor efficacy in killing residual cancer cells for a long time. In recent years, tumor immunotherapy has emerged as a promising method owing to its safety and efficacy with respect to delaying the progression of advanced tumors and protecting postoperative patients against tumor relapse and metastasis...
2018: Journal of Immunology Research
https://www.readbyqxmd.com/read/29785006/the-era-of-immunogenomics-immunopharmacogenomics
#2
REVIEW
Makda Zewde, Kazuma Kiyotani, Jae-Hyun Park, Hua Fang, Kai Lee Yap, Poh Yin Yew, Houda Alachkar, Taigo Kato, Tu H Mai, Yuji Ikeda, Tatsuo Matsuda, Xiao Liu, Lili Ren, Boya Deng, Makiko Harada, Yusuke Nakamura
Although germline alterations and somatic mutations in disease cells have been extensively analyzed, molecular changes in immune cells associated with disease conditions have not been characterized in depth. It is clear that our immune system has a critical role in various biological and pathological conditions, such as infectious diseases, autoimmune diseases, drug-induced skin and liver toxicity, food allergy, and rejection of transplanted organs. The recent development of cancer immunotherapies, particularly drugs modulating the immune checkpoint molecules, has clearly demonstrated the importance of host immune cells in cancer treatments...
May 21, 2018: Journal of Human Genetics
https://www.readbyqxmd.com/read/29749320/combined-treatment-for-gastric-cancer-immunological-approach
#3
Olzhas Zhandossov, Galina Kaussova, Avraam Koten
BACKGROUND/AIMS: Gastric cancer is one of the most common oncological diseases. It can develop in any part of the stomach and spread to other organs, especially the esophagus, lungs, and liver. The aim of our study was to investigate the effectiveness of our proposed therapy. MATERIALS AND METHODS: Our research promises more effective neoadjuvant therapy, including immunotherapy and multi-agent chemotherapy. Of the 62 patients involved in our study, 32 underwent neoadjuvant chemotherapy in combination with surgery, whereas the rest underwent neoadjuvant chemoimmunotherapy with surgery...
March 2018: Turkish Journal of Gastroenterology: the Official Journal of Turkish Society of Gastroenterology
https://www.readbyqxmd.com/read/29740200/emergence-of-immunotherapy-as-a-novel-way-to-treat-hepatocellular-carcinoma
#4
REVIEW
Naofumi Mukaida, Yasunari Nakamoto
Tumor immunity proceeds through multiple processes, which consist of antigen presentation by antigen presenting cells (APCs) to educate effector cells and destruction by the effector cytotoxic cells. However, tumor immunity is frequently repressed at tumor sites. Malignantly transformed cells rarely survive the attack by the immune system, but cells that do survive change their phenotypes to reduce their immunogenicity. The resultant cells evade the attack by the immune system and form clinically discernible tumors...
May 7, 2018: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/29735884/polysaccharides-extracted-from-rhizoma-pleionis-have-antitumor-properties-in-vitro-and-in-an-h22-mouse-hepatoma-ascites-model-in-vivo
#5
Yukun Fang, Anhong Ning, Sha Li, Shaozheng Zhou, Lei Liu, Thomson Patrick Joseph, Mintao Zhong, Jilong Jiao, Wei Zhang, Yonghui Shi, Meishan Zhang, Min Huang
Malignant ascites is a highly severe and intractable complication of advanced or recurrent malignant tumors that is often immunotherapy-resistant. Rhizoma Pleionis is widely used in traditional medicine as an antimicrobial and anticancer agent, but its effectiveness in treating malignant ascites is unclear. In the current study, we investigated the effect of polysaccharides isolated from Rhizoma Pleionis (PRP) on murine hepatocarcinoma H22 cells in an ascites model. We have found that the main components of PRP, that presented a relative molecular weight of 383...
May 7, 2018: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29730556/new-peptide-my1340-revert-the-inhibition-effect-of-vegf-on-dendritic-cells-differentiation-and-maturation-via-blocking-vegf-nrp-1-axis-and-inhibit-tumor-growth-in-vivo
#6
Zheng Mo, Fei Yu, Su Han, Songhua Yang, Liangliang Wu, Peng Li, Shunchang Jiao
The development and clinical application of immunostimulatory therapy provides us a new and exciting strategy in cancer treatment of which the agents act on crucial receptors. Given the fact that Neuropilin-1(NRP-1) is essential for vascular endothelial growth factor (VEGF) to inhibit LPS-dependent maturation of dendritic cells (DCs), it may present a potentially meaningful target in cancer immunotherapy. To explore this hypothesis, we synthesized a novel polypeptide called MY1340 consist of 32 amino acids with the aim of targeting VEGF-NRP-1 axis...
May 3, 2018: International Immunopharmacology
https://www.readbyqxmd.com/read/29727577/carrier-free-pure-nanodrug-formed-by-self-assembly-of-anti-cancer-drug-for-cancer-immune-therapy
#7
Lulu Fan, Bingchen Zhang, Aixiao Xu, Zhichun Shen, Yan Guo, Ruirui Zhao, Huilu Yao, Jing-Wei Shao
Ursolic acid (UA) is a food-plant derived natural product which has good anticancer activities and low toxicity. However, the poor water solubility of UA limits its application in clinic. To address this issue, we developed a carrier-free nanodrug by self-assembly of UA. Here, we showed that UA NPs was near-spherical shape with the size of ~150 nm diameter. UA NPs exhibited higher antiproliferative activity, significantly caused apoptosis, decreased the expression of COX-2/VEGFR2/VEGFA and increased the immunostimulatory activity of TNF-α, IL-6 and IFN-β and decrease the activity of STAT-3 in A549 cells in vitro...
May 4, 2018: Molecular Pharmaceutics
https://www.readbyqxmd.com/read/29705790/immunotherapy-of-hepatocellular-carcinoma
#8
Bernd Heinrich, Carolin Czauderna, Jens U Marquardt
Hepatocellular carcinoma (HCC) is one of the most deadly and rapidly evolving cancers worldwide. The current systemic treatment strategies in advanced tumor stages remain limited despite promising preclinical and early-phase clinical results for some compounds, highlighting an unmet clinical need. Since the majority of HCCs evolve in the background of a chronic inflammatory liver damage, HCCs can be considered a paradigm for inflammation-induced cancers, which renders immunotherapeutic strategies particularly promising for this tumor entity...
2018: Oncology Research and Treatment
https://www.readbyqxmd.com/read/29658563/preclinical-evaluation-of-a-novel-engineered-recombinant-human-anti-cd44v6-antibody-for-potential-use-in-radio-immunotherapy
#9
Anja C Mortensen, Diana Spiegelberg, Anna-Karin Haylock, Hans Lundqvist, Marika Nestor
CD44v6 is overexpressed in a variety of cancers, rendering it a promising target for radio-immunotherapy (RIT). In this study, we have characterized a novel engineered recombinant monoclonal anti-CD44v6 antibody, AbN44v6, and assessed its potential for use in RIT using either 177Lu or 131I as therapeutic radionuclides. In vitro affinity and specificity assays characterized the binding of the antibody labeled with 177Lu, 125I or 131I. The therapeutic effects of 177Lu-AbN44v6 and 131I-AbN44v6 were investigated using two in vitro 3D tumor models with different CD44v6 expression...
April 11, 2018: International Journal of Oncology
https://www.readbyqxmd.com/read/29650841/-a-case-of-advanced-esophageal-cancer-successfully-treated-with-multidisciplinary-therapy
#10
Junji Kawada, Masaya Nishino, Tomoki Hata, Takayuki Ogino, Masateru Okawa, Hiromitsu Hoshino, Miho Okano, Kenichi Nagai, Naruyasu Kakita, Yongkook Kim, Masaki Okuyama, Toshimasa Tsujinaka
We report a case of advanced esophageal cancer that was successfully treated using chemotherapy, operation, and chemoradiotherapy. A 66-year-old man with advanced esophageal cancer(Mt, O-Is, T4[N0.7-stomach], N2, M0, Stage III)was administered chemotherapy(docetaxel[DOC], cisplatin[CDDP], and 5-fluorouracil[5-FU]: DCF). As the esophageal tumor achieved complete clinical response after 2 courses of chemotherapy, lymph node dissection and proximal gastrectomy were performed for the residual tumor. Abdominal CT 3 months after surgery revealed lymph node swelling...
April 2018: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29623110/clinical-assessment-of-immune-related-adverse-events
#11
REVIEW
Aaron Sosa, Esther Lopez Cadena, Cristina Simon Olive, Niki Karachaliou, Rafael Rosell
Immunotherapy through checkpoint inhibitors is now standard practice for a growing number of cancer types, supported by overall improvement of clinical outcomes and better tolerance. One anti-CTLA-4 antibody (ipilimumab), two anti-PD-1 antibodies (pembrolizumab and nivolumab) and three anti-PD-L1 antibodies (atezolizumab, avelumab and durvalumab) have been approved for clear benefits across diverse trials. Adverse events of an immune nature associated with these agents frequently affect the skin, colon, endocrine glands, lungs and liver...
2018: Therapeutic Advances in Medical Oncology
https://www.readbyqxmd.com/read/29621772/a-complete-pathological-response-to-pembrolizumab-following-ex-vivo-liver-resection-in-a-patient-with-colorectal-liver-metastases
#12
Maria Baimas-George, Erin Baker, Michal Kamionek, J Stuart Salmon, Amit Sastry, David Levi, Dionisios Vrochides
Advances in the systemic treatment of stage IV colorectal cancer with liver metastases has offered improved survival rates for patients who otherwise face a dismal prognosis. However, a pathologically complete response (PCR) to chemotherapy for colorectal liver metastases is still rare, and its significance is not fully understood. In this case report, we describe a patient who achieved PCR after neoadjuvant immunotherapy with pembrolizumab and a left hepatectomy using an ex vivo resection technique.
April 5, 2018: Chemotherapy
https://www.readbyqxmd.com/read/29606020/hepatitis-b-reactivation-in-the-treatment-of-non-hodgkin-lymphoma
#13
Matthew Kelling, Lubomir Sokol, Samir Dalia
Chronic active hepatitis B infection (HBV) has been implicated in lymphomagenesis of non-Hodgkin lymphoma (NHL). Treatment of cancer including NHL with chemotherapy or immunotherapy can lead to HBV reactivation in previously infected patients. Serological testing of HBV prior to initiation of this therapy is recommended by several national and international medical agencies and expert panels. Patients with positive hepatitis B surface antigen (HBsAg) and anti-hepatitis B core antibody (anti-HBc ab) need to start antiviral therapy with entecavir or tenofovir prior to initiation of chemotherapy or immunotherapy and continue this treatment for 6 to 12 months after completion of cancer therapy to avoid late HBV reactivation...
January 2018: Cancer Control: Journal of the Moffitt Cancer Center
https://www.readbyqxmd.com/read/29601672/mri-guided-interventional-natural-killer-cell-delivery-for-liver-tumor-treatment
#14
Zhanliang Su, Xifu Wang, Linfeng Zheng, Tianchu Lyu, Matteo Figini, Bin Wang, Daniel Procissi, Junjie Shangguan, Chong Sun, Liang Pan, Lei Qin, Bin Zhang, Yury Velichko, Riad Salem, Vahid Yaghmai, Andrew C Larson, Zhuoli Zhang
While natural killer (NK) cell-based adoptive transfer immunotherapy (ATI) provides only modest clinical success in cancer patients. This study was hypothesized that MRI-guided transcatheter intra-hepatic arterial (IHA) infusion permits local delivery to liver tumors to improve outcomes during NK-based ATI in a rat model of hepatocellular carcinoma (HCC). Mouse NK cells were labeled with clinically applicable iron nanocomplexes. Twenty rat HCC models were assigned to three groups: transcatheter IHA saline infusion as the control group, transcatheter IHA NK infusion group, and intravenous (IV) NK infusion group...
March 30, 2018: Cancer Medicine
https://www.readbyqxmd.com/read/29599403/-18-f-fdg-pet-ct-can-predict-development-of-thyroiditis-due-to-immunotherapy-for-lung-cancer
#15
Naghmehossadat Eshghi, Linda Garland, Emily Saghar Nia, Robert Betancourt, Elizabeth Krupinski, Phillip H Kuo
Objective: For patients undergoing immunotherapy with nivolumab for lung cancer, determine if increased18 F-FDG uptake in the thyroid gland predicts development of thyroiditis with subsequent hypothyroidism. Secondarily, determine if18 F-FDG uptake in the thyroid gland correlates with administered cycles of nivolumab. Materials and Methods: Retrospective chart review over 2 years found 18 lung cancer patients treated with nivolumab and with18 F-FDG PET/CT scans pre- and during therapy. Standardized uptake value (SUV) mean and maximum and total lesion glycolysis (TLG) of the thyroid gland were measured...
March 29, 2018: Journal of Nuclear Medicine Technology
https://www.readbyqxmd.com/read/29593893/identifying-and-managing-the-adverse-effects-of-immune-checkpoint-blockade
#16
REVIEW
Arthur Winer, J Nicholas Bodor, Hossein Borghaei
Immunotherapy has revolutionized the field of oncology. By inhibiting the cytotoxic T-lymphocyte-associated protein (CTLA-4) and programmed death-1 (PD-1) immune checkpoint pathways, multiple studies have demonstrated greatly improved survival in locally advanced and metastatic cancers including melanoma, renal, lung, gastric, and hepatocellular carcinoma. Trials in other malignancies are ongoing, and undoubtedly the number of drugs in this space will grow beyond the six currently approved by the Food and Drug Administration...
February 2018: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/29564186/immunomodulation-in-hepatocellular-cancer
#17
REVIEW
Sunyoung Lee, Matthew Loecher, Renuka Iyer
Hepatocellular carcinoma (HCC) is the fastest growing malignancy in the United States in relation to mortality. HCC relies on a complex immunosuppressive network to modify the host immune system and evade destruction. Intrinsic to the liver's function and anatomy, native hepatic and immune cells produce many inhibitory cytokines that promote tolerogenicity and limit immune response. Since the introduction of sorafenib in 2008, no treatment has been able to demonstrate improved survival in patients with advanced HCC post disease progression treated with sorafenib...
February 2018: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/29552184/%C3%AE-%C3%AE-t-cell-mediated-individualized-immunotherapy-for-hepatocellular-carcinoma-considering-clinicopathological-characteristics-and-immunosuppressive-factors
#18
Wei Tian, Jun Ma, Ruyi Shi, Chongren Ren, Jiefeng He, Haoliang Zhao
Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer. γδ T cells have been revealed to be promising candidates for immunotherapy in patients with HCC. However, the use of these cells in clinical practice has been demonstrated to be challenging. In the present study, γδ T cells isolated from the peripheral blood of patients with HCC (n=83) and healthy donors (n=15) were characterized. Flow cytometry was used to analyze the proportion, phenotype, tumor-killing capacity and cytokine secretion of regulatory T cells (Tregs) and γδ T17 cells in peripheral blood samples prior to and following amplification...
April 2018: Oncology Letters
https://www.readbyqxmd.com/read/29552119/microrna-374b-inhibits-liver-cancer-progression-via-down-regulating-programmed-cell-death-1-expression-on-cytokine-induced-killer-cells
#19
Fen Huang, Bo Wang, Jiangzheng Zeng, Shenggang Sang, Junhua Lei, Yanda Lu
Programmed cell death-1 (PD-1) is an oncogene associated with suppressing proliferation and cytokine production of T cells in the progression of liver cancer. microRNAs (miRs) regulate gene expression via specific binding to the target 3'untranslated region of mRNA. In the present study, miR-374b was indicated to interact with PD-1 and affect the tumor-targeting capacity of cytokine-induced killer (CIK) cells. miR-374b inhibitor significantly increased PD-1 expression in CIK cells. A synthetic small interfering (si)RNA targeting PD-1 was employed to silence the expression level of PD-1 in CIK cells...
April 2018: Oncology Letters
https://www.readbyqxmd.com/read/29539626/risk-of-liver-toxicity-with-nivolumab-immunotherapy-in-cancer-patients
#20
Kevin Zarrabi, Shenhong Wu
BACKGROUND: Nivolumab is approved for the treatment of many cancers. This meta-analysis was conducted to determine the risk of hepatotoxicity with nivolumab therapy. METHODS: An analysis from all phase I-III clinical trials up to December 2016 examining nivolumab was conducted. Data on elevations in aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were extracted from the safety profiles of each trial. Incidence and relative risk (RR) were calculated using random- or fixed-effects models with 95% confidence intervals (CIs)...
2018: Oncology
keyword
keyword
113389
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"